Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: A case–control study in Nepalese children 5 years after immunization

Genetic and Phenotypic Properties of Vero Cell-Adapted Japanese Encephalitis Virus SA14-14-2 Vaccine Strain Variants and a Recombinant Clone, Which Demonstrates Attenuation and Immunogenicity in Mice

“…15,17,18 Immunization with JEV SA14-14-2 has been shown to result in 88-96% efficacy after a single dose (10 5.4 -10 6.8 plaque-forming units [PFU]/dose, depending on the study [19][20][21][22] ) and has been administered to millions of children with no reported serious adverse events. 15,[23][24][25][26] The World Health Organization (WHO) prequalified the JEV SA14-14-2 vaccine in October of 2013.…”

Immunogenicity and safety of currently available Japanese encephalitis vaccines: A systematic review

“…In another large-scale study 51 on the safety and efficacy of live attenuated SA14-14-2 virus vaccine compromising 335941 children, no allergic response or encephalitis was observed. Several subjects reported local swelling or low-grade fever.…”

“…51 Live attenuated SA14-14-2 virus vaccine was first used outside of China among Korean children, Sohn et al 52 evaluated the immunogenicity in 68 infants aged 1-3 years old. 65 (96%) of the subjects were seroprotected after the primary vaccination, and the GMT was 188.…”

Japanese Encephalitis vaccine: Need of the hour in endemic states of India

“…However, more recent case control studies from Nepal have shown efficacies of 99% at 12-15 mo and 96% at 5 y with a single dose of the vaccine. 17 Per recent WHO reports and Cochrane meta-analysis, no serious adverse effects have been reported with this vaccine. The Government of India should implement universal immunization with this vaccine in all…”